Should We Interfere with the Interleukin-6 Receptor During COVID-19: What Do We Know So Far?

Abstract Severe manifestations of COVID-19 consist of acute respiratory distress syndrome due to an initially local reaction leading to a systemic inflammatory response that results in hypoxia. Many therapeutic approaches have been attempted to reduce the clinical consequences of an excessive immune response to viral infection. To date, systemic corticosteroid therapy is still the most effective intervention. More recently, new hope has emerged with the use of interleukin (IL)-6 receptor inhibitors (tocilizumab and sarilumab). However, the great heterogeneity of the methodology and results of published studies obfuscate the true value of this treatment, leading to a confusing synthesis in recent meta-analyses, and the persistence of doubts in terms of patient groups and the appropriate time to treat. Moreover, their effects on the anti-infectious or pro-healing response are still poorly studied. This review aims to clarify the potential role of IL-6 receptor inhibitors in the treatment of severe forms of COVID-19..

Medienart:

E-Artikel

Erscheinungsjahr:

2022

Erschienen:

2022

Enthalten in:

Zur Gesamtaufnahme - volume:83

Enthalten in:

Drugs - 83(2022), 1 vom: 12. Dez., Seite 1-36

Sprache:

Englisch

Beteiligte Personen:

Plocque, Alexia [VerfasserIn]
Mitri, Christie [VerfasserIn]
Lefèvre, Charlène [VerfasserIn]
Tabary, Olivier [VerfasserIn]
Touqui, Lhousseine [VerfasserIn]
Philippart, Francois [VerfasserIn]

Links:

Volltext [lizenzpflichtig]

BKL:

44.40$jPharmazie$jPharmazeutika

44.38$jPharmakologie

Anmerkungen:

© The Author(s), under exclusive licence to Springer Nature Switzerland AG 2022. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

doi:

10.1007/s40265-022-01803-2

funding:

Förderinstitution / Projekttitel:

PPN (Katalog-ID):

OLC2133341323

Zugang & Verfügbarkeit




Zugehörige Publikationen/Bände

    Haven't found what you're looking for?